CNY Means Business · Audio / VideoThe latest podcast episode
CNY Means Business official YouTube channel artworkCNY MEANS
BUSINESSCENTRAL NEW YORK BUSINESS

BROADCAST GRAPHICS / NORTH COUNTRY

ON-AIR GRAPHIC.

Novo's investigational CagriSema, a GLP-1 and amylin analog, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes & Endocrinology

CNY Means Business title graphic: Novo's investigational CagriSema, a GLP-1 and amylin analog, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes & Endocrinology, Source: NNY360 North Country
Download SVGOriginal reporting: NNY360 North Country ↗

TV graphics are generated from licensed illustrative photography and the article's credited headline. Publisher photographs are not reused without permission.